克服胰腺癌的耐药性。
Overcoming drug resistance in pancreatic cancer.
机构信息
Baylor College of Medicine, Molecular Surgeon Research Center, Elkins Pancreas Center, Michael E. DeBakey Department of Surgery, Houston, Texas 77030, USA.
出版信息
Expert Opin Ther Targets. 2011 Jul;15(7):817-28. doi: 10.1517/14728222.2011.566216. Epub 2011 Mar 11.
INTRODUCTION
Pancreatic cancer has the worst survival rate of all cancers. The current standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this treatment is poor and overall survival has not improved for decades. Drug resistance (both intrinsic and acquired) is thought to be a major reason for the limited benefit of most pancreatic cancer therapies.
AREAS COVERED
Previous studies have indicated various mechanisms of drug resistance in pancreatic cancer, including changes in individual genes or signaling pathways, the influence of the tumor microenvironment, and the presence of highly resistant stem cells. This review summarizes recent advances in the mechanisms of drug resistance in pancreatic cancer and potential strategies to overcome this.
EXPERT OPINION
Increasing drug delivery efficiency and decreasing drug resistance is the current aim in pancreatic cancer treatment, and will also benefit the treatment of other cancers. Understanding the molecular and cellular basis of drug resistance in pancreatic cancer will lead to the development of novel therapeutic strategies with the potential to sensitize pancreatic cancer to chemotherapy, and to increase the efficacy of current treatments in a wide variety of human cancers.
简介
胰腺癌是所有癌症中存活率最差的。转移性胰腺癌的当前标准治疗方法是吉西他滨，然而，这种治疗的成功率很低，几十年来总体生存率并未提高。耐药性（内在和获得性）被认为是大多数胰腺癌治疗获益有限的主要原因。
涵盖领域
先前的研究表明了胰腺癌中各种耐药机制，包括单个基因或信号通路的变化、肿瘤微环境的影响以及高度耐药干细胞的存在。本综述总结了胰腺癌耐药机制的最新进展以及克服耐药性的潜在策略。
专家意见
提高药物输送效率和降低耐药性是目前胰腺癌治疗的目标，也将有益于其他癌症的治疗。了解胰腺癌耐药性的分子和细胞基础将导致开发新的治疗策略，有可能使胰腺癌对化疗敏感，并提高各种人类癌症中当前治疗方法的疗效。
Zotero 插件